Orion - Other information disclosed according to the rules of the Exchange

297,000 Orion Corporation A shares converted into B shares

ORION CORPORATION       STOCK EXCHANGE RELEASE         16 APRIL 2019 at 9.00
a.m. EEST



297,000 Orion Corporation A shares converted into B shares


In accordance with Section 3 of the Articles of Association of Orion
Corporation, 297,000 A shares have been converted into 297,000 B shares. The
conversion has been entered into the Trade Register on 16 April 2019.

The total number of shares in Orion Corporation is 141,257,828 which, after the
conversion, consists of 36,823,346 A shares and 104,434,482 B shares. The number
of votes of the company's shares is after the conversion 840,901,402.



Orion Corporation



Olli Huotari               Jari Karlson
SVP, Corporate Functions   CFO




Contact person:
Terhi Ormio, Vice President, Communications, tel. +358 10 426 4646



Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi/en



Orion is a globally operating Finnish pharmaceutical company - a builder of
well-being. Orion develops, manufactures and markets human and veterinary
pharmaceuticals and active pharmaceutical ingredients. The company is
continuously developing new drugs and treatment methods. The core therapy areas
of Orion's pharmaceutical R&D are central nervous system (CNS) disorders,
oncology and respiratory diseases for which Orion develops inhaled Easyhaler®
pulmonary drugs. Orion's net sales in 2018 amounted to EUR 977 million and the
company had about 3,200 employees at the end of the year. Orion's A and B shares
are listed on Nasdaq Helsinki.

[]